About a year after halving its…
About a year after halving its staff in a clinical [...]
A phase 2b lupus trial of…
A phase 2b lupus trial of Alumis’ envudeucitinib has missed [...]
The 2026 IPO streak continues as…
The 2026 IPO streak continues as Electra Therapeutics has filed [...]
AstraZeneca’s oral relaxin…
AstraZeneca’s oral relaxin agonist delivered encouraging phase 2b results in [...]
Eli Lilly has struck a deal to…
Eli Lilly has struck a deal to acquire Merida Biosciences [...]
Following Merck and Moderna’s…
Following Merck and Moderna’s phase 3 triumph with a Keytruda-paired [...]
AusperBio Therapeutics has raised…
AusperBio Therapeutics has raised $120 million in series C funds [...]
BioXcel Therapeutics has filed for…
BioXcel Therapeutics has filed for bankruptcy and lined up a [...]
Roche’s Genentech is paying…
Roche’s Genentech is paying DualityBio $45 million upfront for rights [...]
Vivace Therapeutics has…
Vivace Therapeutics has named Craig Gibbs, Ph.D., as its new president [...]